Dana Investment Advisors Inc. Raises Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Dana Investment Advisors Inc. boosted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 55.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,407 shares of the company’s stock after acquiring an additional 8,009 shares during the period. Dana Investment Advisors Inc. owned 0.07% of TransMedics Group worth $1,397,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Arizona State Retirement System lifted its position in TransMedics Group by 1.9% during the 4th quarter. Arizona State Retirement System now owns 9,668 shares of the company’s stock valued at $603,000 after acquiring an additional 184 shares during the period. Venturi Wealth Management LLC lifted its position in TransMedics Group by 33.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after acquiring an additional 219 shares during the period. National Bank of Canada FI lifted its position in TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after acquiring an additional 262 shares during the period. Quarry LP lifted its position in TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after acquiring an additional 312 shares during the period. Finally, Farther Finance Advisors LLC lifted its position in TransMedics Group by 187.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after acquiring an additional 316 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on TMDX shares. Canaccord Genuity Group lowered their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Piper Sandler reduced their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Robert W. Baird reduced their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, February 5th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $67.46 on Friday. The company has a 50 day moving average price of $68.30 and a 200-day moving average price of $97.72. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37. The firm has a market capitalization of $2.27 billion, a PE ratio of 71.77 and a beta of 2.12. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.